دورية أكاديمية
أعرض في EDS

Synthesis, Biological Evaluation and Molecular Modeling Studies of Naphthoquinone Sulfonamides and Sulfonate Ester Derivatives as P2X7 Inhibitors.

التفاصيل البيبلوغرافية
العنوان: Synthesis, Biological Evaluation and Molecular Modeling Studies of Naphthoquinone Sulfonamides and Sulfonate Ester Derivatives as P2X7 Inhibitors.
المؤلفون: Pacheco PAF; Department of Organic Chemistry, Institute of Chemistry, Federal Fluminense University, Niterói 24020-141, Brazil., Gonzaga DTG; Departament of Pharmacy, West Zone Campus, State University of Rio de Janeiro, Rio de Janeiro 23070-200, Brazil., von Ranke NL; Department of Pharmaceuticals and Medicines, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21941-170, Brazil., Rodrigues CR; Department of Pharmaceuticals and Medicines, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21941-170, Brazil., da Rocha DR; Department of Organic Chemistry, Institute of Chemistry, Federal Fluminense University, Niterói 24020-141, Brazil., da Silva FC; Department of Organic Chemistry, Institute of Chemistry, Federal Fluminense University, Niterói 24020-141, Brazil., Ferreira VF; Department of Organic Chemistry, Institute of Chemistry, Federal Fluminense University, Niterói 24020-141, Brazil., Faria RX; Evaluation and Promotion of the Ambiental Health Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, Brazil.; Postgraduate Program in Sciences and Biotechnology, Institute of Biology, Federal Fluminense University, Niterói 24210-130, Brazil.
المصدر: Molecules (Basel, Switzerland) [Molecules] 2023 Jan 06; Vol. 28 (2). Date of Electronic Publication: 2023 Jan 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c1995-
مواضيع طبية MeSH: Purinergic P2X Receptor Antagonists*/pharmacology , Purinergic P2X Receptor Antagonists*/chemistry , Naphthoquinones*/pharmacology , Naphthoquinones*/chemistry, Sulfonamides/pharmacology ; Molecular Docking Simulation ; Receptors, Purinergic P2X7 ; Adenosine Triphosphate/metabolism
مستخلص: ATP acts in the extracellular environment as an important signal, activating a family of receptors called purinergic receptors. In recent years, interest in the potential therapeutics of purinergic components, including agonists and antagonists of receptors, has increased. Currently, many observations have indicated that ATP acts as an important mediator of inflammatory responses and, when found in high concentrations in the extracellular space, is related to the activation of the P2X7 purinergic receptor. In this sense, the search for new inhibitors for this receptor has attracted a great deal of attention in recent years. Sulfonamide derivatives have been reported to be potent inhibitors of P2X receptors. In this study, ten naphthoquinone sulfonamide derivatives and five naphthoquinone sulfonate ester derivatives were tested for their inhibitory activity on the P2X7 receptor expressed in peritoneal macrophages. Some compounds showed promising results, displaying IC 50 values lower than that of A740003. Molecular docking and dynamic studies also indicated that the active compounds bind to an allosteric site on P2X7R. The binding free energy indicates that sulfonamides have an affinity for the P2X7 receptor similar to A740003. Therefore, the compounds studied herein present potential P2X7R inhibition.
References: J Mol Graph. 1996 Feb;14(1):33-8, 27-8. (PMID: 8744570)
Bioorg Med Chem. 2014 Jan 1;22(1):54-88. (PMID: 24314880)
Front Mol Neurosci. 2020 Jul 31;13:124. (PMID: 32848594)
Clin Exp Pharmacol Physiol. 2019 Jun;46(6):513-526. (PMID: 30834550)
Proteins. 1990;8(3):195-202. (PMID: 2281083)
Am J Physiol Cell Physiol. 2005 Feb;288(2):C260-71. (PMID: 15469955)
Purinergic Signal. 2016 Mar;12(1):59-67. (PMID: 26739702)
J Pharmacol Exp Ther. 2000 Dec;295(3):862-9. (PMID: 11082418)
Prog Med Chem. 2014;53:65-100. (PMID: 24418608)
Biomed Pharmacother. 2021 Oct;142:112006. (PMID: 34392085)
J Comput Chem. 2004 Jul 15;25(9):1157-74. (PMID: 15116359)
Bioorg Med Chem. 2019 Apr 15;27(8):1449-1455. (PMID: 30528164)
Mol Biol Cell. 2005 Jul;16(7):3260-72. (PMID: 15901833)
Arthritis Rheumatol. 2018 Apr;70(4):484-495. (PMID: 29287308)
Nat Rev Drug Discov. 2015 Nov;14(11):751-8. (PMID: 26435527)
Exp Physiol. 2014 Jan;99(1):16-34. (PMID: 24078669)
Recent Pat Anticancer Drug Discov. 2019;14(1):32-38. (PMID: 30652649)
J Bioenerg Biomembr. 2019 Aug;51(4):277-290. (PMID: 31256283)
Pharmacol Rev. 2022 Apr;74(2):340-372. (PMID: 35302044)
Mol Pharmacol. 2000 Jul;58(1):82-8. (PMID: 10860929)
J Bioenerg Biomembr. 2022 Dec;54(5-6):227-239. (PMID: 36070071)
Purinergic Signal. 2022 Mar;18(1):83-92. (PMID: 34799827)
FASEB J. 2010 Feb;24(2):337-45. (PMID: 19812374)
Pharmacol Rev. 1998 Sep;50(3):413-92. (PMID: 9755289)
Philos Trans R Soc Lond B Biol Sci. 2016 Aug 5;371(1700):. (PMID: 27377721)
Glia. 2016 Oct;64(10):1772-87. (PMID: 27219534)
J Comput Chem. 2010 Jan 30;31(2):455-61. (PMID: 19499576)
Front Pharmacol. 2018 Feb 06;9:52. (PMID: 29467654)
Inflamm Bowel Dis. 2015 Oct;21(10):2247-53. (PMID: 26197451)
J Chem Theory Comput. 2012 Sep 11;8(9):3314-21. (PMID: 26605738)
Purinergic Signal. 2018 Mar;14(1):1-18. (PMID: 29164451)
Pharm Pat Anal. 2017 Mar;6(2):61-76. (PMID: 28248151)
Naunyn Schmiedebergs Arch Pharmacol. 2010 Jul;382(1):73-87. (PMID: 20508916)
Cell Death Dis. 2021 Nov 16;12(12):1088. (PMID: 34789738)
Front Chem. 2019 Apr 30;7:261. (PMID: 31134177)
Pharmaceutics. 2022 Apr 21;14(5):. (PMID: 35631497)
Bioorg Chem. 2020 Nov;104:104278. (PMID: 33010623)
J Mol Model. 2007 Dec;13(12):1173-213. (PMID: 17828561)
Immunity. 2017 Jul 18;47(1):15-31. (PMID: 28723547)
Bio Protoc. 2019 Nov 05;9(21):e3410. (PMID: 33654910)
Eur J Biochem. 2000 Sep;267(17):5421-6. (PMID: 10951200)
Eur J Med Chem. 2018 Jan 1;143:1361-1372. (PMID: 29133043)
Biochem Pharmacol. 2021 May;187:114361. (PMID: 33309519)
Nucleic Acids Res. 2015 Jul 1;43(W1):W174-81. (PMID: 25883148)
Front Pharmacol. 2020 Jun 04;11:793. (PMID: 32581786)
Elife. 2016 Dec 09;5:. (PMID: 27935479)
J Cheminform. 2012 Aug 13;4(1):17. (PMID: 22889332)
J Mol Model. 2013 Jan;19(1):1-32. (PMID: 23187683)
Purinergic Signal. 2009 Mar;5(1):63-73. (PMID: 18568426)
Br J Pharmacol. 2021 Feb;178(3):489-514. (PMID: 33125712)
Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489. (PMID: 33237286)
Pharmacol Rev. 2014 Jul;66(3):638-75. (PMID: 24928329)
Purinergic Signal. 2020 Sep;16(3):327-336. (PMID: 32583309)
Scand J Immunol. 2021 Feb;93(2):e12960. (PMID: 32797724)
Nucleic Acids Res. 1994 Nov 11;22(22):4673-80. (PMID: 7984417)
معلومات مُعتمدة: 316568/2021-0 National Council for Scientific and Technological Development; Financial Code 001 Coordenação de Aperfeicoamento de Pessoal de Nível Superior; E-26/203.246/2017 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; E-26/211.025/2019 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; E-26/200.982/2021 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; E-26/211.343/2021 Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
فهرسة مساهمة: Keywords: ATP; biomass; heterocycles; inflammation; naphthoquinones; sulfonamides
المشرفين على المادة: 0 ((N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide))
0 (Purinergic P2X Receptor Antagonists)
0 (Sulfonamides)
0 (Naphthoquinones)
0 (Receptors, Purinergic P2X7)
8L70Q75FXE (Adenosine Triphosphate)
تواريخ الأحداث: Date Created: 20230121 Date Completed: 20230124 Latest Revision: 20230201
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9866630
DOI: 10.3390/molecules28020590
PMID: 36677652
قاعدة البيانات: MEDLINE
الوصف
تدمد:1420-3049
DOI:10.3390/molecules28020590